ATE425791T1 - Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten - Google Patents

Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten

Info

Publication number
ATE425791T1
ATE425791T1 AT05107042T AT05107042T ATE425791T1 AT E425791 T1 ATE425791 T1 AT E425791T1 AT 05107042 T AT05107042 T AT 05107042T AT 05107042 T AT05107042 T AT 05107042T AT E425791 T1 ATE425791 T1 AT E425791T1
Authority
AT
Austria
Prior art keywords
gastrointestinal
treatment
combination
itriglumide
ppi
Prior art date
Application number
AT05107042T
Other languages
English (en)
Inventor
Lucio Claudio Rovati
Gianfranco Caselli
Amato Massimo Maria D
Antonio Giordani
Francesco Makovec
Original Assignee
Rottapharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm Spa filed Critical Rottapharm Spa
Application granted granted Critical
Publication of ATE425791T1 publication Critical patent/ATE425791T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT05107042T 2005-07-29 2005-07-29 Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten ATE425791T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05107042A EP1747800B1 (de) 2005-07-29 2005-07-29 Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten

Publications (1)

Publication Number Publication Date
ATE425791T1 true ATE425791T1 (de) 2009-04-15

Family

ID=35351644

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05107042T ATE425791T1 (de) 2005-07-29 2005-07-29 Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten

Country Status (9)

Country Link
US (2) US7846921B2 (de)
EP (1) EP1747800B1 (de)
JP (1) JP2009502867A (de)
AT (1) ATE425791T1 (de)
AU (1) AU2006274905B2 (de)
CA (1) CA2616941C (de)
DE (1) DE602005013372D1 (de)
ES (1) ES2324354T3 (de)
WO (1) WO2007014872A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110280941A1 (en) * 2008-12-11 2011-11-17 Mefford Scientific, Llc Compositions of proton pump inhibitors and insulin secretagogues, and methods of their use to treat diabetes
AU2012351342A1 (en) * 2011-12-16 2014-07-24 Atopix Therapeutics Limited Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
BR112016011727A2 (pt) 2013-11-22 2017-08-08 CL BioSciences LLC Antagonistas de gastrina para o tratamento e prevenção de osteoporose
TWI675660B (zh) * 2014-04-30 2019-11-01 國立臺灣大學 作為ｄ-胺基酸氧化酶抑制劑之已知化合物之用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012817A1 (en) * 1991-12-20 1993-07-08 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
EP1644043A1 (de) * 2003-05-27 2006-04-12 ALTANA Pharma AG Pharmazeutische kombinationen aus einem protonenpumpenhemmer und einer verbindung zur modifizierung der gastrointestinalen motilität

Also Published As

Publication number Publication date
ES2324354T3 (es) 2009-08-05
EP1747800B1 (de) 2009-03-18
CA2616941C (en) 2014-01-21
CA2616941A1 (en) 2007-02-08
DE602005013372D1 (de) 2009-04-30
US7846921B2 (en) 2010-12-07
US20080004303A1 (en) 2008-01-03
EP1747800A1 (de) 2007-01-31
AU2006274905A1 (en) 2007-02-08
US20110045033A1 (en) 2011-02-24
WO2007014872A1 (en) 2007-02-08
JP2009502867A (ja) 2009-01-29
AU2006274905B2 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
DE602005015577D1 (de) Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
ATE410161T1 (de) 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
DE602007008434D1 (de) Rezeptoren
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
DE602007009095D1 (de) Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
DE602006009968D1 (de) N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
DE602006006354D1 (de) Pinolensäure zur Behandlung von Übergewicht
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
JO2645B1 (en) Vehicles
NO20075074L (no) Kinazolinon T-type-kalsiumkanalantagonister
ATE512948T1 (de) Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen
NO20071272L (no) Modulatorer av muskarine reseptorer.
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
ATE505468T1 (de) N-gebundene heterocyclische antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
MX2009003981A (es) Agentes moduladores del receptor de calcio.
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
ATE425791T1 (de) Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties